<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865124</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-000564</org_study_id>
    <secondary_id>1R01HL087060-01A2</secondary_id>
    <nct_id>NCT00865124</nct_id>
  </id_info>
  <brief_title>Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease</brief_title>
  <official_title>Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aldosterone is a significant mediator of cardiovascular injury associated with heart failure
      and the cardiovascular benefits of mineralocorticoid receptor blockade are additive to those
      of angiotensin converting enzyme inhibitors or angiotensin II (ANGII) receptor blockers. This
      study will test the hypothesis that mineralocorticoid receptor (MR) antagonists exert
      beneficial cardiovascular effects, specifically by decreasing vascular injury and improving
      vascular function. A randomized, double-blind study will be conducted, in which participants
      with Type 2 Diabetes Mellitus will undergo a series of assessments to test heart, blood
      vessel, and kidney function at baseline, and after 2 and 6 months of treatment with one of
      the following drugs:

        1. spironolactone

        2. hydrochlorothiazide (HCTZ) plus potassium

        3. placebo

      In the event of insufficient funds, randomization to the placebo arm will be stopped and
      primary assessment of outcomes will occur at baseline and after 6 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Coronary Flow Reserve From Baseline to 6 Months</measure>
    <time_frame>Baseline and six months</time_frame>
    <description>Coronary flow reserve (CFR), or myocardial perfusion reserve, was assessed via cardiac positron emission tomography (PET). CFR is the ratio of adenosine-stimulated blood flow through myocardium to resting blood flow through myocardium. An improvement in coronary flow reserve is beneficial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mitral Annulus Velocities on Tissue Doppler (Delta E/e' Ratio), a Measure of Diastolic Function</measure>
    <time_frame>Baseline and six months</time_frame>
    <description>Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Annulus Velocities on Tissue Doppler (Delta E/e' Ratio), a Measure of Diastolic Function (With Angiotensin II)</measure>
    <time_frame>Baseline and six months</time_frame>
    <description>Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment; and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Plasma Flow</measure>
    <time_frame>Baseline and six months</time_frame>
    <description>Renal vasculature was assessed by examining renal plasma flow, or para-aminohippurate (PAH) clearance, basally and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Spironolactone (mineralocorticoid receptor [MR] blockade)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide + potassium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25 mg capsule daily for 6 months</description>
    <arm_group_label>Spironolactone (mineralocorticoid receptor [MR] blockade)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide + potassium</intervention_name>
    <description>hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily</description>
    <arm_group_label>Hydrochlorothiazide + potassium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule daily</description>
    <arm_group_label>Placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-70 years

          -  type 2 diabetes mellitus

          -  with or without hypertension

        Exclusion Criteria:

          -  ischemic changes on resting electrocardiogram,

          -  clinical evidence of heart disease (angina, heart failure, unstable
             angina),cerebrovascular or peripheral vascular disease,

          -  significant cardiac arrhythmias,

          -  aortic stenosis,

          -  2nd or 3rd degree atrio-ventricular block, sinus node disease, or symptomatic
             bradycardia,

          -  bronchospastic lung disease with active wheezing,

          -  known hypersensitivity to adenosine,

          -  hemoglobin A1C (HbA1c) &gt; 8.5%, *

          -  gout (If not already taking HCTZ),

          -  the use of Rosiglitazone,**

          -  estimated glomerular filtration rate (eGFR) &lt; 60 ml/min,

          -  serum potassium &gt; 5.0 mmol/L,

          -  use of potassium-sparing diuretics,**

          -  current smoker,*

          -  pregnancy,

          -  renal disease not related to diabetes mellitus,

          -  uncontrolled hypertension, systolic blood pressure (BP) &gt;160 mm Hg and diastolic BP
             &gt;100 mm Hg,*

          -  use of cyclic hormone replacement therapy

          -  past intolerance of angiotensin-converting enzyme (ACE) inhibitor therapy

          -  other major medical illnesses. Participants with evidence of a previous myocardial
             infarction on the first adenosine-stimulated positron emission tomography (PET) study
             will be withdrawn from the study.

          -  Screening systolic blood pressure &lt; 105 mm Hg off of anti-hypertensive medications

               -  Participants can enroll in study and proceed with in-patient evaluations if
                  during the run-in period adjustments of medications, diet and habits lead to
                  improved glucose control [equivalent to HbA1c &lt;8.5%, controlled hypertension and
                  cessation of smoking.

                    -  Participants who are currently taking these medications will not qualify for
                       a screening visit. If medications were recently stopped by the participant's
                       physician, he or she may be screened but the baseline assessment protocol
                       must occur 3 months after stopping.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail K Adler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <results_first_submitted>April 12, 2017</results_first_submitted>
  <results_first_submitted_qc>May 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Gail Kurr Adler</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Spironolactone (MR Blockade)</title>
          <description>25 mg capsule daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Hydrochlorothiazide + Potassium</title>
          <description>Hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo capsule daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Spironolactone (MR Blockade)</title>
          <description>Spironolactone: 25 mg capsule daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Hydrochlorothiazide + Potassium</title>
          <description>Hydrochlorothiazide + potassium: hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 mEq capsule daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo Capsule</title>
          <description>Placebo: Placebo capsule daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="6"/>
                    <measurement group_id="B2" value="53" spread="7"/>
                    <measurement group_id="B3" value="55" spread="10"/>
                    <measurement group_id="B4" value="54.72" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Coronary Flow Reserve From Baseline to 6 Months</title>
        <description>Coronary flow reserve (CFR), or myocardial perfusion reserve, was assessed via cardiac positron emission tomography (PET). CFR is the ratio of adenosine-stimulated blood flow through myocardium to resting blood flow through myocardium. An improvement in coronary flow reserve is beneficial.</description>
        <time_frame>Baseline and six months</time_frame>
        <population>All participants with data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Spironolactone (MR Blockade)</title>
            <description>25 mg capsule daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide + Potassium</title>
            <description>Hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 mEq capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Coronary Flow Reserve From Baseline to 6 Months</title>
          <description>Coronary flow reserve (CFR), or myocardial perfusion reserve, was assessed via cardiac positron emission tomography (PET). CFR is the ratio of adenosine-stimulated blood flow through myocardium to resting blood flow through myocardium. An improvement in coronary flow reserve is beneficial.</description>
          <population>All participants with data available for this outcome measure.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.83"/>
                    <measurement group_id="O2" value="-0.10" spread="0.65"/>
                    <measurement group_id="O3" value="0.02" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mitral Annulus Velocities on Tissue Doppler (Delta E/e’ Ratio), a Measure of Diastolic Function</title>
        <description>Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment.</description>
        <time_frame>Baseline and six months</time_frame>
        <population>All participants with data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Spironolactone (MR Blockade)</title>
            <description>25 mg capsule daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide + Potassium</title>
            <description>Hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 mEq capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mitral Annulus Velocities on Tissue Doppler (Delta E/e’ Ratio), a Measure of Diastolic Function</title>
          <description>Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment.</description>
          <population>All participants with data available for this outcome measure.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.61"/>
                    <measurement group_id="O2" value="0.06" spread="1.35"/>
                    <measurement group_id="O3" value="0.64" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Annulus Velocities on Tissue Doppler (Delta E/e’ Ratio), a Measure of Diastolic Function (With Angiotensin II)</title>
        <description>Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment; and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II.</description>
        <time_frame>Baseline and six months</time_frame>
        <population>All participants with data available for this outcome measure at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Spironolactone (MR Blockade)</title>
            <description>25 mg capsule daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide + Potassium</title>
            <description>Hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 mEq capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Annulus Velocities on Tissue Doppler (Delta E/e’ Ratio), a Measure of Diastolic Function (With Angiotensin II)</title>
          <description>Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment; and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II.</description>
          <population>All participants with data available for this outcome measure at the given time-point.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment, E/e’, baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="1.93"/>
                    <measurement group_id="O2" value="6.72" spread="1.93"/>
                    <measurement group_id="O3" value="6.55" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-treatment, E/e’, Post-ANGII</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.09" spread="1.96"/>
                    <measurement group_id="O2" value="7.06" spread="1.66"/>
                    <measurement group_id="O3" value="6.70" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-treatment, E/e’, baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" spread="1.57"/>
                    <measurement group_id="O2" value="7.03" spread="1.83"/>
                    <measurement group_id="O3" value="7.35" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-treatment, E/e’, Post-ANGII</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" spread="2.53"/>
                    <measurement group_id="O2" value="5.83" spread="2.82"/>
                    <measurement group_id="O3" value="7.48" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Plasma Flow</title>
        <description>Renal vasculature was assessed by examining renal plasma flow, or para-aminohippurate (PAH) clearance, basally and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II.</description>
        <time_frame>Baseline and six months</time_frame>
        <population>All participants with data available for this outcome measure at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Spironolactone (MR Blockade)</title>
            <description>25 mg capsule daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide + Potassium</title>
            <description>Hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 mEq capsule daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Plasma Flow</title>
          <description>Renal vasculature was assessed by examining renal plasma flow, or para-aminohippurate (PAH) clearance, basally and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II.</description>
          <population>All participants with data available for this outcome measure at the given time-point.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment, PAH clearance, baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527" spread="76"/>
                    <measurement group_id="O2" value="508" spread="82"/>
                    <measurement group_id="O3" value="518" spread="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-treatment, PAH clearance, Post-ANGII</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442" spread="75"/>
                    <measurement group_id="O2" value="417" spread="49"/>
                    <measurement group_id="O3" value="436" spread="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-treatment, PAH clearance, baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518" spread="97"/>
                    <measurement group_id="O2" value="500" spread="80"/>
                    <measurement group_id="O3" value="491" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-treatment, PAH clearance, Post-ANGII</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423" spread="89"/>
                    <measurement group_id="O2" value="415" spread="61"/>
                    <measurement group_id="O3" value="427" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Adverse events are reported for participants who received study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Spironolactone (MR Blockade)</title>
          <description>25 mg capsule daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Hydrochlorothiazide + Potassium</title>
          <description>Hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 mEq capsule daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo capsule daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased potassium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Reversible ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stress-induced ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Atrial septal aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Thoracic vertebral hemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vertebral degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung nodule</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nodular opacity in the lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dilated pulmonary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gail K. Adler</name_or_title>
      <organization>Brigham and Women’s Hospital</organization>
      <phone>617-732-5661</phone>
      <email>gadler@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

